News

Class I innovative drug of JYMed have made significant progress, Laipushutai is expected to become the first line of UC drugs.

On June 29, 2017, the development of Laipushutai, the class I innovative medicine with the cooperative development of JYMed and Guangzhou Linkhealth Medical Technology Co., Ltd., has made significant progress. The drug’s IND declaration has been accepted by the CFDA. JYMed and Guangzhou Lin... Read More

News & EventsThe Peptide Products Division in JYMed has flawlessly passed on-site inspection from FDA.

Warmly congratulate our Polypeptide Products Division for successfully passing the US FDA on-site inspection with “zero defects”! Passing the FDA on-site inspection with “zero defects” is a major event in our cGMP development history. It not only means that our API has obt... Read More